-
Some speculations on the myeloproliferative syndromes.
PMID: 14820991 [PubMed - indexed for MEDLINE]
-
Cited by 39 PubMed Central articles
-
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, et al.
Blood. 2008 Jun 15; 111(12):5663-71. Epub 2007 Nov 5.
[Blood. 2008]
-
ReviewThe chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Kaushansky K.
Best Pract Res Clin Haematol. 2007 Mar; 20(1):5-12.
[Best Pract Res Clin Haematol. 2007]
-
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.
PLoS One. 2006 Dec 20; 1:e18. Epub 2006 Dec 20.
[PLoS One. 2006]
- » See all...